Verified factor-similar pair

ISCG vs VTWO

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
81
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • VTWO has the higher backtested relative Sharpe (0.866 vs 0.731).
  • ISCG is cheaper on dividend valuation (99 vs 116, where 100 is each fund's historical median).
  • VTWO has the stronger regression fit (adjusted R-squared 0.991 vs 0.960).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

ISCG

iShares Morningstar Small-Cap Growth ETF
SMB
Adj. R2
0.960
Rel. Sharpe
0.731
Mkt beta
1.03
AUM
US$908M
MER
0.06%
Valuation
99

VTWO

Vanguard Russell 2000 ETF
SMB
Adj. R2
0.991
Rel. Sharpe
0.866
Mkt beta
1.02
AUM
US$14.8B
MER
0.06%
Valuation
116

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
ISCG
+0.80
|t|
+25.6
VTWO
+0.85
|t|
+47.9
diff -0.05
HML
ISCG
-0.24
|t|
-7.9
VTWO
+0.12
|t|
+6.8
diff -0.36
RMW
ISCG
-0.17
|t|
-4.5
VTWO
-0.10
|t|
-4.8
diff -0.08
CMA
ISCG
-0.05
|t|
-1.1
VTWO
-0.06
|t|
-2.2
diff +0.01
UMD
ISCG
+0.09
|t|
+5.0
VTWO
+0.07
|t|
+5.2
diff +0.03

Why This Pair Matches

Exposure level
77
Exposure shape
95
Mkt beta diff
0.01
Rel. Sharpe diff
0.136

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

ISCG fund page VTWO fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.